China’s Innovent says its GLP-1 works better than Novo’s semaglutide in diabetes study
SHANGHAI, Oct 27 (Reuters) – China’s Innovent Biologics (1801.HK)opens new tabsaidopens new tabon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients…